- Aldevron and Minaris have renewed and expanded a licensing agreement for an off-the-shelf lentiviral plasmid system used in gene-modified cell therapy applications.
- The agreement supports access to plasmids across research, GMP-Source™ quality grade, and full cGMP manufacturing to help developers accelerate development timelines.
Aldevron and Minaris have renewed a licensing agreement to expand access to a proprietary lentiviral plasmid system designed for gene-modified cell therapy applications.
The agreement extends Aldevron’s collaboration with Oxgene, a Minaris brand focused on lentiviral plasmid technologies. Under the updated arrangement, Aldevron will continue manufacturing and supplying the plasmids across research, GMP-Source™ quality grade, and full cGMP standards. The companies stated that the offering is intended to support developers seeking regulatory-ready starting materials for cell and gene therapy programs.
The expanded platform includes Aldevron’s pALD-Lenti plasmid system, a four-plasmid platform developed for lentiviral vector production. According to the companies, the system supports applications including CAR-T, TCR-T, and other gene-modified cell therapies. The companies added that providing the platform off the shelf is intended to reduce supply chain complexity, shorten lead times, and accelerate development activities.
“By delivering phase appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability.”
Venkata Indurthi, Chief Scientific Officer for Aldevron
The companies stated that the renewed agreement further integrates Oxgene’s plasmid engineering and vector design capabilities with Minaris’ global CDMO and contract manufacturing operations. Aldevron said the collaboration aligns with its strategy to provide scalable plasmid DNA manufacturing solutions for advanced therapy development programs.
